7-Ethyl-10-hydroxycamptothecin CAS 86639-52-3

Product Description:

Product Name: 7-Ethyl-10-hydroxycamptothecin CAS NO: 86639-52-3

Synonyms:

7-10-hydroxycamptothecin;

(4S)-4,9-Dihydroxy-4α,11-diethyl-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14-dione;

Irinotecan Related Compound B (10 mg) ((S)-4,11-diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione);

Chemical & Physical Properties:

Appearance: Light-yellow solid

Assay :≥99.00%

Density: 1.51 g/cm3

Boiling Point: 810.3℃at 760 mmHg

Melting Point: 217℃

Flash Point: 443.8℃

Refractive Index: 21.5 ° (C=0.2, THF)

Storage Condition: -20℃

Safety Information:

RTECS: UQ0491000

HS Code: 2942000000

Hazard Code:T

Risk Statement: R25

Safety Statement: S45

WGK Germany: 3

Hazard Class: 6.1

Packing Group: Ⅲ

SN-38 is an antineoplastic drug. It is the active metabolite of irinotecan (an analog of camptothecin - a topoisomerase I inhibitor) but has 1000 times more activity than irinotecan itself. In vitro cytotoxicity assays show that the potency of SN-38 relative to irinotecan varies from 2- to 2000-fold.

SN38 is formed via hydrolysis of irinotecan by carboxylesterases and metabolized via glucuronidation by UGT1A1.

The variant of UGT1A1 in ~10% of Caucasians which leads to poor metabolism of SN-38 predicts irinotecan toxicity, as it is then less easily excreted from the body in its SN-38 glucuronide form.

SN-38 and its glucuronide are lost into the bile and feces. It can cause the symptoms of diarrhoea and myelosuppression experienced by ~25% of the patients administered irinotecan.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.